Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Deanna, Saunders"'
Autor:
Arif Ali Awan, Deanna Saunders, Gregory Pond, Caroline Hamm, Nadia Califaretti, Mihaela Mates, Vikaash Kumar, Mohammed F. K. Ibrahim, Ana-Alicia Beltran-Bless, Lisa Vandermeer, John Hilton, Mark Clemons
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1278-1290 (2024)
For early-stage hormone receptor (HR)-positive and HER2-negative breast cancer, tools to estimate treatment benefit include free and publicly available algorithms (e.g., PREDICT 2.1) and expensive molecular assays (e.g., Oncotype DX). There remains a
Externí odkaz:
https://doaj.org/article/59ac03d441804b9a97079eb978d6a8a8
Autor:
Susan Dent, Dean Fergusson, Olexiy Aseyev, Carol Stober, Gregory Pond, Arif A. Awan, Sharon F. McGee, Terry L. Ng, Demetrios Simos, Lisa Vandermeer, Deanna Saunders, John F. Hilton, Brian Hutton, Mark Clemons
Publikováno v:
Current Oncology, Vol 28, Iss 6, Pp 5073-5083 (2021)
Purpose: The optimal frequency for cardiac monitoring of left ventricular ejection fraction (LVEF) in patients receiving trastuzumab-based therapy for early breast cancer (EBC) is unknown. We conducted a randomized controlled trial comparing 3- versu
Externí odkaz:
https://doaj.org/article/af20337c49a349a1b33516454764a8cc
Autor:
Marie-France Savard, Mashari Jemaan Alzahrani, Deanna Saunders, Lynn Chang, Angel Arnaout, Terry L. Ng, Muriel Brackstone, Lisa Vandermeer, Tina Hsu, Ari Ali Awan, Katherine Cole, Gail Larocque, Mark Clemons
Publikováno v:
Current Oncology, Vol 28, Iss 6, Pp 5215-5226 (2021)
Older patients with lower-risk hormone receptor-positive (HR+) breast cancer are frequently offered both radiotherapy (RT) and endocrine therapy (ET) after breast-conserving surgery (BCS). A survey was performed to assess older patients’ experience
Externí odkaz:
https://doaj.org/article/be0393d15e4040a2b885877b2e669db2
Management Strategies for Older Patients with Low-Risk Early-Stage Breast Cancer: A Physician Survey
Autor:
Mashari Alzahrani, Mark Clemons, Lynn Chang, Lisa Vendermeer, Angel Arnaout, Gail Larocque, Katherine Cole, Tina Hsu, Deanna Saunders, Marie-France Savard
Publikováno v:
Current Oncology, Vol 29, Iss 1, Pp 1-13 (2021)
When managing older patients with lower-risk hormone-receptor-positive (HR+), HER2 negative (HER2−) early-stage breast cancer (EBC), the harms and benefits of adjuvant therapies should be taken into consideration. A survey was conducted among Canad
Externí odkaz:
https://doaj.org/article/5af5145ba17a4a0baa6f785943263e70
Autor:
Deanna Saunders, Michelle Liu, Lisa Vandermeer, Mashari Jemaan Alzahrani, Brian Hutton, Mark Clemons
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 3959-3977 (2021)
We reviewed patient and health care provider (HCP) surveys performed through the REaCT program. The REaCT team has performed 15 patient surveys (2298 respondents) and 13 HCP surveys (1033 respondents) that have addressed a broad range of topics in br
Externí odkaz:
https://doaj.org/article/b691134d772d41e091bd9e6e399d6bf9
Autor:
Mark Clemons, Dean Fergusson, Anil A. Joy, Kednapa Thavorn, Judith Meza-Junco, Julie Price Hiller, John Mackey, Terry Ng, Xiaofu Zhu, Mohammed F.K. Ibrahim, Marta Sienkiewicz, Deanna Saunders, Lisa Vandermeer, Gregory Pond, Bassam Basulaiman, Arif Awan, Lacey Pitre, Nancy A. Nixon, Brian Hutton, John F. Hilton
Publikováno v:
Breast, Vol 58, Iss , Pp 42-49 (2021)
Background: Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetaxel-cyclophosphamide (TC) chemotherapy for early-stage breast cancer (EBC). A pragmatic randomised
Externí odkaz:
https://doaj.org/article/7167d8bf23184b0bbe70775be20aa64b
Autor:
Sharon McGee, Mashari AlZahrani, Carol Stober, Terry L. Ng, Katherine Cole, Gail Larocque, Arif Awan, Sandeep Sehdev, John Hilton, Lisa Vandermeer, Brian Hutton, Gregory Pond, Deanna Saunders, Mark Clemons
Publikováno v:
Journal of Bone Oncology, Vol 27, Iss , Pp 100351- (2021)
Background: Despite the increasing use of adjuvant bisphosphonates for early stage breast cancer (EBC), little is known about the patient experience with such treatments. A patient survey was performed to identify current prescribing practices, perce
Externí odkaz:
https://doaj.org/article/f1411dede35d4fa1a6439a23035a2735
Autor:
Arif Awan, Terry Ng, Henry Conter, William Raskin, Carol Stober, Demetrios Simos, Greg Pond, Sukhbinder Dhesy-Thind, Mihaela Mates, Vikaash Kumar, Dean Fergusson, Brian Hutton, Deanna Saunders, Lisa Vandermeer, Mark Clemons
Publikováno v:
Journal of Bone Oncology, Vol 26, Iss , Pp 100343- (2021)
Background: Adjuvant zoledronate is widely used in patients with early stage breast cancer (EBC), but its optimal duration and dosing interval is still unknown. While a single-dose of zoledronate can improve bone density for many years, a proper eval
Externí odkaz:
https://doaj.org/article/9cbee11243204b0a8c3c062e7a1485a9
Autor:
Marie-France Savard, Mohammed Ibrahim, Gregory Pond, Deanna Saunders, Lisa Vandermeer, Ana-Alicia Beltran-Bless, Lesley Fallowfield, Mark Clemons
Publikováno v:
Cancer Research. 82:OT1-11
Background. Endocrine therapy (ET) is the mainstay treatment for hormonal receptor positive (HR+) breast cancer. ET non-compliance and non-persistence vary from 30 to 70% and are associated with reduced disease-free and overall survival. ET side effe
Autor:
Lisa Vandermeer, Mark Clemons, Michelle Liu, Deanna Saunders, Mashari Alzahrani, Brian Hutton
Publikováno v:
Current Oncology
Current Oncology, Vol 28, Iss 337, Pp 3959-3977 (2021)
Current Oncology, Vol 28, Iss 337, Pp 3959-3977 (2021)
We reviewed patient and health care provider (HCP) surveys performed through the REaCT program. The REaCT team has performed 15 patient surveys (2298 respondents) and 13 HCP surveys (1033 respondents) that have addressed a broad range of topics in br